Artist rendering of AstraZeneca's planned antibody-drug conjugate facility in Singapore. (Credit: AstraZeneca)
May 20, 2024 06:07 AM EDTUpdated 10:02 AM
Manufacturing

As­traZeneca ear­marks $1.5B for end-to-end ADC fac­to­ry in Sin­ga­pore

Anna Brown

News Reporter

As­traZeneca said on Mon­day morn­ing it is build­ing a new an­ti­body-drug con­ju­gate fa­cil­i­ty in Sin­ga­pore worth $1.5 bil­lion.

The UK phar­ma said this will be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

Up­dat­ed: Telix Phar­ma­ceu­ti­cals pulls Nas­daq list­ing plans just be­fore trad­ing was to start

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

BIO's new CEO takes a pa­tri­ot­ic piv­ot to win back Con­gress, push­ing in­dus­try to re­think Chi­na re­la­tion­ship

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times